IFNG and neoplasm: Indeed, CCR4 antagonism in combination with sorafenib showed enhanced anti-tumor efficacy by transforming the immune landscape toward anti-tumor immunity through overall reduction in Tregs, diminishing proportions of CCR4+ TIL-Tregs, decreasing PD-1+CD8+ T cells, and enhancing IFN-γ+CD8+ T cells [75].